| P2093 | author name string | G Davies | |
| | D Mitchison | |
| P2860 | cites work | Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model | Q21144660 |
| | Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis | Q24609567 |
| | Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis | Q24624866 |
| | The mechanism of action of PA-824: Novel insights from transcriptional profiling | Q24643238 |
| | STREPTOMYCIN treatment of pulmonary tuberculosis | Q24672289 |
| | Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis | Q24796366 |
| | Role of individual drugs in the chemotherapy of tuberculosis | Q28138632 |
| | Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications | Q28146009 |
| | The curious characteristics of pyrazinamide: a review | Q28191713 |
| | The diarylquinoline TMC207 for multidrug-resistant tuberculosis | Q28247333 |
| | An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence | Q28378895 |
| | Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum | Q28472502 |
| | Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis | Q28476110 |
| | Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy | Q28477566 |
| | A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis | Q29617342 |
| | A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis | Q34009677 |
| | Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients | Q34045233 |
| | Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis | Q34272283 |
| | Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis | Q34340538 |
| | Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis | Q34952765 |
| | Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis | Q35102656 |
| | The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. | Q35191432 |
| | Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability | Q35532853 |
| | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy | Q35636012 |
| | Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis | Q35647811 |
| | Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. | Q36153946 |
| | The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug | Q36263124 |
| | Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections | Q36393640 |
| | Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis | Q36669451 |
| | Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption | Q36702972 |
| | Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis | Q36803956 |
| | A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India | Q36880282 |
| | Prevalence of tuberculosis among close family contacts of tuberculous patients in South India, and influence of segregation of the patient on early attack rate. | Q36913563 |
| | Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis | Q37392767 |
| | The near future: improving the activity of rifamycins and pyrazinamide | Q37728596 |
| | Sputkm conversion and the metabolism of isoniazid | Q77118109 |
| | Development of rifapentine: the way ahead | Q77124255 |
| | The heat resistance of tubercle bacilli in the lungs of infected mice | Q79100361 |
| | Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis | Q82960790 |
| | Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification | Q83286782 |
| | Experimental models of tuberculosis: can we trust the mouse? | Q84293966 |
| | Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins | Q84572163 |
| | Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa--fifth investigation. A co-operative study in East African hospitals, clinics and laboratories with the collaboration of the East African and Briti | Q93695452 |
| | Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review. | Q37863250 |
| | Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs | Q37874018 |
| | Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide | Q39501282 |
| | Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells | Q39664217 |
| | Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. | Q42115114 |
| | The early bactericidal activity of drugs in patients with pulmonary tuberculosis | Q42257164 |
| | The early bactericidal activity of amikacin in pulmonary tuberculosis. | Q43642695 |
| | The early bactericidal activity of streptomycin. | Q44084221 |
| | Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days | Q44273153 |
| | Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. | Q45089281 |
| | Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. | Q46029821 |
| | The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis | Q46417486 |
| | Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis | Q46484820 |
| | Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients | Q46573371 |
| | Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens | Q46641553 |
| | The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis | Q46804015 |
| | Formation and resuscitation of "non-culturable" cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase. | Q51718626 |
| | Cumulative effects of pulsed exposures of mycobacterium tuberculosis to isoniazid. | Q53788380 |
| | Treatment of pulmonary tuberculosis with short course chemotherapy in south India--5-year follow up. | Q54340326 |
| | Drug resistance in tuberculosis control. | Q54406091 |
| | The action of antituberculosis drugs in short-course chemotherapy. | Q54445022 |
| | The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. | Q54506766 |
| | Activity of rifampicin on experimental tuberculosis in mice. The development of resistance to rifampicin. Therapeutic effects of combinations of different drugs with rifampicin | Q54683351 |
| | Chemotherapy of pulmonary tuberculosis. | Q55124959 |
| | Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema | Q58643378 |
| | Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis | Q59689693 |
| | First-line chemotherapy in the retreatment of bacteriological relapses of pulmonary tuberculosis following a shortcourse regimen | Q66703147 |
| | Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study | Q67492764 |
| | Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month | Q67985481 |
| | Counts of viable tubercle bacilli in sputum related to smear and culture gradings | Q67994055 |
| | Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study | Q68881337 |
| | Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study | Q70151486 |
| | Inhibition by streptomycin of tubercle bacilli within cultured human macrophages | Q70504799 |
| | Pharmacological Study of Rifampicin after Repeated High Dosage during Intermittent Combined Therapy. I. Variation of the Rifampicin Serum Levels (947 Determinations) | Q70679887 |
| | Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study | Q72621504 |
| | ISONIAZID in the treatment of pulmonary tuberculosis; second report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee | Q73049269 |
| | What is the 'right' dose of rifampin? | Q73287274 |
| | A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council | Q73595253 |
| | Effects of isoniazid on pyridoxine metabolism | Q73658569 |
| | TREATMENT of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee | Q73953257 |
| | A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid, and streptomycin plus para-aminosalicylic acid, in pulmonary tuberculosis | Q74045725 |
| | The bactericidal activities of antituberculous drugs | Q74131736 |
| | The prevalence of drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis; a national survey, 1955-56 | Q74475362 |
| | Bacteriological aspects of a survey of the incidence of drug-resistant tubercle bacilli among untreated patients | Q74475365 |
| | How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis | Q74485447 |
| | TREATMENT of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid; a Medical Research Council investigation | Q75461673 |
| | The segregation of streptomycin-resistant variants of Mycobacterium tuberculosis into groups with characteristic levels of resistance | Q75832252 |
| P433 | issue | 6 | |
| P921 | main subject | tuberculosis | Q12204 |
| | pyrazinoic acid | Q7263414 |
| | chemotherapy | Q974135 |
| P304 | page(s) | 724-732 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | International Journal of Tuberculosis and Lung Disease | Q15767020 |
| P1476 | title | The chemotherapy of tuberculosis: past, present and future | |
| P478 | volume | 16 | |